PERSPECTA

News from every angle

← Back to headlines

Citi Initiates Buy Rating for Ionis, Alnylam, BioMarin

Citi has started coverage on Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and BioMarin Pharmaceutical with a Buy rating, citing positive catalyst and growth outlooks.

19 May, 18:01 — 19 May, 18:01
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed1h ago

Ionis, Alnylam, BioMarin up as Citi starts at Buy on catalyst and growth outlook

Read full article →

Related Stories

Oil Jumps Above $100 After US-Iran Talks Fail

just now

Revolut to Relocate Hungarian Accounts and Adjust Fees

13m ago

Portugal Government Clashes with Court of Accounts Over State Spending Control

13m ago

Athens Stock Exchange Slides Amid Late Selling Spree

14m ago